

AMENDMENT

In the Claims

The following Listing of Claims, in which deleted text appears as ~~struck through~~ and inserted text appears underlined, will replace all prior listings, and versions, of claims in the application.

Listing of Claims

Claims 1 – 10 (cancelled)

Claim 11 (original): An antibody or antibody fragment thereof, wherein said antibody comprises a variable heavy chain amino acid sequence of SEQ ID NO. 78 and a variable light chain amino acid sequence of SEQ ID NO. 48.

Claim 12 (original): The antibody according to Claim 11, wherein said antibody is monoclonal.

Claim 13 (currently amended): The ~~monoclonal~~ antibody according to Claim ~~12~~11, wherein said ~~monoclonal~~ antibody is a ~~chimeric antibody~~, humanized antibody, ~~or fully human antibody~~.

Claim 14 (original): The antibody fragment according to Claim 11, wherein said antibody fragment is a Fab fragment, (Fab')₂ fragment, or Fv fragment.

Claim 15 (original): The antibody according to Claim 11, wherein said antibody is conjugated to a cytotoxic agent.

Claim 16 (original): A pharmaceutical composition comprising the antibody or antibody fragment according to Claim 11 and a physiologically acceptable pharmaceutical carrier.

Claim 17 (original): A method of preventing or reducing severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof, comprising

administering to said subject an effective amount of an antibody or antibody fragment according to Claim 11.

Claim 18 (currently amended): The method according to Claim 17, wherein said inflammatory bowel disease is Crohn's disease ~~or ulcerative colitis~~.

Claim 19 (original): The method according to Claim 17, wherein said antibody inhibits at least one biological activity of IP-10.

Claim 20 (currently amended): The method according to Claim 17, further ~~comprises~~ comprising administering an immunosuppressive agent to the subject.

Claim 21 (withdrawn - new): The method according to Claim 17, wherein said inflammatory bowel disease is ulcerative colitis.

Claim 22 (new): The antibody according to Claim 11, wherein said antibody is a chimeric antibody.

Claim 23 (new): The antibody according to Claim 11, wherein said antibody is a fully human antibody.